-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Protagenic Therapeutics, Inc.\new quarterly/annual Earnings Per Share, Diluted history and growth rate from Q2 2010 to Q2 2024.
- Protagenic Therapeutics, Inc.\new Earnings Per Share, Diluted for the quarter ending June 30, 2024 was -0.36 USD/shares, a 28.6% decline year-over-year.
- Protagenic Therapeutics, Inc.\new Earnings Per Share, Diluted for the twelve months ending June 30, 2024 was -1.45 USD/shares.
- Protagenic Therapeutics, Inc.\new annual Earnings Per Share, Diluted for 2023 was -1.15 USD/shares, a 40.2% decline from 2022.
- Protagenic Therapeutics, Inc.\new annual Earnings Per Share, Diluted for 2022 was -0.82 USD/shares.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)